Skip to content
X-twitter-square Linkedin Instagram Facebook-square Youtube

NASDAQ: HELP |  CBOE CA: HELP

  • Our Work
    • Clinical Trials
    • Development Pipeline
    • HLP003
    • HLP004
    • Intellectual Property
    • EMBARK
    • Scientific Publications
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
    • Governance
  • About Us
    • Our Team
    • Our Focus
    • Join Us
    • Contact Us
  • Our Work
    • Clinical Trials
    • Development Pipeline
    • HLP003
    • HLP004
    • Intellectual Property
    • EMBARK
    • Scientific Publications
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
    • Governance
  • About Us
    • Our Team
    • Our Focus
    • Join Us
    • Contact Us

Archives: Press Releases

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

– Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration (“FDA”) guidance on trial design, with the potential to significantly reduce drug development timelines – – First known BTD granted by the FDA for an

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

– Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (“MDD”) – – Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – TORONTO–(BUSINESS WIRE)–  Cybin Inc.

← Previous
X-twitter-square Linkedin Instagram Facebook-square Youtube

OUR WORK

  • Clinical Trials
  • Development Pipeline
  • HLP003
  • HLP004
  • Intellectual Property
  • EMBARK
  • Scientific Publications
  • Clinical Trials
  • Development Pipeline
  • HLP003
  • HLP004
  • Intellectual Property
  • EMBARK
  • Scientific Publications
INVESTORS
  • Overview
  • News
  • Events & Presentations
  • Financials
  • Governance
  • Overview
  • News
  • Events & Presentations
  • Financials
  • Governance

ABOUT US

  • Our Team
  • Our Focus
  • Join Us
  • Contact Us
  • Our Team
  • Our Focus
  • Join Us
  • Contact Us

TRADE

  • NASDAQ: HELP
  • CBOE CA: HELP
  • Helus Pharma© 2026. All rights reserved.
  • Privacy Policy
  • Employee Privacy Policy
  • Privacy Notice